Cover Image

CHD6 drives an immunosuppressive vascular ecotype and therapy resistance in hepatocellular carcinoma

Fuente: Zenodo

Saved in:

Bibliographic Details
Main Authors:	Fan, Xutong, Zhang, Min
Format:	Recurso digital
Published:	Zenodo 2026
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tumor-associated CD19$^+$ macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma
by: Wang, Junli, et al.
Published: (2025)

Emerging nanomedicine strategies for hepatocellular carcinoma therapy
by: Chen Guo, et al.
Published: (2024)

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives
by: Jian‐Jian Chen, et al.
Published: (2024)

Systemic therapies in hepatocellular carcinoma: A revolution?
by: Marta Fortuny, et al.
Published: (2024)

Exosomal miR‐93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway
by: Yuanpeng Bao, et al.
Published: (2024)

Effectiveness of add‐on acetazolamide in children with drug‐resistant CHD2‐related epilepsy and in a zebrafish CHD2 model
by: Gia Melikishvili, et al.
Published: (2024)

Mitochondrial metabolism: A moving target in hepatocellular carcinoma therapy
by: Monika Komza, et al.
Published: (2024)

PPM1G‒MET axis sustains AKT signaling to drive Twist‐associated EMT and drug resistance in hepatocellular carcinoma
by: Weixun Wu, et al.
Published: (2026)

Host ANGPTL2 establishes an immunosuppressive tumor microenvironment and resistance to immune checkpoint therapy
by: Shinsei Yumoto, et al.
Published: (2024)

Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma
by: Dai Lian, et al.
Published: (2024)

MRI for hepatocellular carcinoma and the role of abbreviated MRI for surveillance of hepatocellular carcinoma
by: Soe Thiha Maung, et al.
Published: (2024)

Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma
by: Jiayin Lin, et al.
Published: (2026)

Methylation in hepatocellular carcinoma
by: REGINA M. SANTELLA
Published: (2007)

Epidemiology of hepatocellular carcinoma
by: RAYMUNDO PARANÁ
Published: (2007)

Natural products targeting macroautophagy signaling in hepatocellular carcinoma therapy: Recent evidence and perspectives
by: Yuan Chen, et al.
Published: (2024)

Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma
by: Mosunmoluwa Oyenuga, et al.
Published: (2025)

Recent advances in systemic therapies for unresectable hepatocellular carcinoma and their impact on clinical outcomes
by: Kyoko Oura
Published: (2025)

USP22 promotes the proliferation and Sorafenib resistance of hepatocellular carcinoma cells via its deubiquitinase activity
by: Xiaochen Wang, et al.
Published: (2025)

NS3 of hepatitis C virus drives hepatocellular carcinoma progression through a novel RNA‐interference pathway
by: Yajun Liang, et al.
Published: (2025)

Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study
by: Jun‐Zhe Yi, et al.
Published: (2024)

Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma
by: Hironori Ochi, et al.
Published: (2025)

A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
by: Tetsu Tomonari, et al.
Published: (2025)

Whole‐exome sequencing‐based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma
by: Yichao Bu, et al.
Published: (2024)

TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll‐like‐receptor signalling
by: Fatma El Zahraa Ammar Mohamed, et al.
Published: (2024)

Perfusion of hepatocellular carcinomas measured by diffusion‐derived vessel density biomarker: Higher hepatocellular carcinoma perfusion than earlier intravoxel incoherent motion reports
by: Xin‐Ming Li, et al.
Published: (2024)

CircETV6 acts as an oncogenic driver in hepatocellular carcinoma progression
by: Xiaoqin Li, et al.
Published: (2024)

Delta virus infection and hepatocellular carcinoma
by: Maurizio Bonacini
Published: (2024)

Intrahepatic splenosis mimicking hepatocellular carcinoma
by: Martina Rosi, et al.
Published: (2024)

Clinical and laboratory features of hepatocellular carcinoma
by: MARIA C. LONDOÑO
Published: (2007)

Immunosupression in liver transplant for hepatocellular carcinoma
by: JUAN-CARLOS RESTREPO
Published: (2007)

Hepatitis infections, aflatoxin and hepatocellular carcinoma
by: PIERRE HAINAUT
Published: (2007)

The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma
by: Shuwen Kuang, et al.
Published: (2024)

Metabolic‐associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy
by: NM Batt, et al.
Published: (2024)

Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy
by: Sha She, et al.
Published: (2024)

FactCHD: Benchmarking Fact-Conflicting Hallucination Detection
by: Chen, Xiang, et al.
Published: (2023)

Targeting the NSUN5-circPPAP2A axis reverses immunosuppression and sensitizes renal cell carcinoma to anti-PD-1 therapy
by: First Affiliated Hospital of Guangzhou Medical University
Published: (2026)

Genotype-phenotype modeling of light ecotypes in reveals genomic signatures of ecotypic divergence.
by: Brenner, Evan, et al.
Published: (2026)

Sister Mary Joseph's nodule in hepatocellular carcinoma
by: Arpit Shastri, et al.
Published: (2024)

Opportunities to improve surveillance of hepatocellular carcinoma in Australia
by: Jess Howell, et al.
Published: (2025)

Proteomics for the early diagnosis and treatment of hepatocellular carcinoma
by: VIJAY KUMAR
Published: (2007)